918 related articles for article (PubMed ID: 33796113)
1. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
2. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
4. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease.
Kim H; Lee EJ; Kim S; Choi LK; Kim K; Kim HW; Kim KK; Lim YM
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32184342
[TBL] [Abstract][Full Text] [Related]
5. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
[TBL] [Abstract][Full Text] [Related]
6. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
[TBL] [Abstract][Full Text] [Related]
7. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.
Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R
Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595
[TBL] [Abstract][Full Text] [Related]
8. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
[TBL] [Abstract][Full Text] [Related]
9. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults.
Duan Z; Feng J
J Clin Neurosci; 2022 Jul; 101():89-93. PubMed ID: 35569419
[TBL] [Abstract][Full Text] [Related]
13. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
[TBL] [Abstract][Full Text] [Related]
14. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
[TBL] [Abstract][Full Text] [Related]
15. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders.
Liu C; Zhao L; Fan P; Ko H; Au C; Ng A; Au L; Wong A; Kermode AG; Mok V; Yan Y; Qiu W; Lau AY
J Clin Neurosci; 2021 Jan; 83():108-111. PubMed ID: 33317883
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
17. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
19. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
Jurynczyk M; Probert F; Yeo T; Tackley G; Claridge TDW; Cavey A; Woodhall MR; Arora S; Winkler T; Schiffer E; Vincent A; DeLuca G; Sibson NR; Isabel Leite M; Waters P; Anthony DC; Palace J
Acta Neuropathol Commun; 2017 Dec; 5(1):95. PubMed ID: 29208041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
